Pharmaceutical companies from the Chinese mainland and Taiwan convened for the first forum on cross-strait industrial cooperation on Monday in Taipei, calling for further ties to boost mutual development, reports Xinhua, China’s official news agency.
The forum, co-organized by the Taiwan-based Institute for Biotechnology and Medicine Industry (IBMI) and China Pharmaceutical Innovation and Research Development Association, has set up a platform for pharmaceutical enterprises across the strait to deepen cooperation in new drug development and grab a larger share of the global market.
Chen Weijao, chairman of the IBMI, said Taiwan has many talents conducting clinical studies and novel drug R&D, accompanied by rigid regulation of pharmaceutical standards, while the Chinese mainland has a huge potential drug market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze